Could an asthma drug shield young hearts and kidneys from diabetes damage?
NCT ID NCT07409714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether montelukast, a medicine used for asthma, can help protect the kidneys and blood vessels in 50 teens and young adults (ages 14-24) with type 2 diabetes. The drug works by blocking harmful inflammatory chemicals linked to diabetes complications. Researchers will measure changes in kidney blood flow and artery health over 6 months to see if this approach could reduce long-term risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?